Overcoming barriers to adult immunization.
The herpes zoster vaccine has proven to reduce the incidence of herpes zoster and postherpetic neuralgia, a debilitating condition that can remain for years after zoster rash has resolved. However, few eligible adults have received the vaccine. Findings from survey-based studies on patient uptake of influenza and pneumococcal polysaccharide vaccines suggest that physician recommendations and standing orders can increase vaccine uptake. However, certain barriers unique to zoster vaccination (eg, reimbursement concerns) will need to be addressed.
High
Kevin P
KP
Section of Infectious Diseases, Wake Forest University, Winston-Salem, NC 27157-1042, USA. khigh@wfubmc.edu
D000328:Adult; D000368:Aged; D006297:Health Services Accessibility; D006562:Herpes Zoster / Q000453:epidemiology* / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D010342:Patient Acceptance of Health Care
D053061:Herpes Zoster Vaccine